Related references
Note: Only part of the references are listed.Local and systemic responses to SARS-CoV-2 infection in children and adults
Masahiro Yoshida et al.
NATURE (2022)
Covid-19 Vaccine Effectiveness in New York State
Eli S. Rosenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
Fang Xu et al.
EMERGING MICROBES & INFECTIONS (2022)
High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
Eva-Maria Jacobsen et al.
NATURE COMMUNICATIONS (2022)
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial
Jing-Xin Li et al.
LANCET RESPIRATORY MEDICINE (2022)
Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination
Bruno Pozzetto et al.
NATURE (2021)
Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
Janeri Froberg et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2021)
Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis
Yunzhi Ling et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu et al.
LANCET (2021)
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
Shipo Wu et al.
LANCET INFECTIOUS DISEASES (2021)
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Tina Schmidt et al.
NATURE MEDICINE (2021)
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros-Martins et al.
NATURE MEDICINE (2021)
Effectiveness of mRNA Covid-19 Vaccine among US Health Care Personnel
T. Pilishvili et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Yinon M. Bar-On et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma
Hans Verkerke et al.
TRANSFUSION (2021)
SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection
Carolyn A. Cohen et al.
NATURE COMMUNICATIONS (2021)
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
Catherine M. Brown et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Immune system development varies according to age, location, and anemia in African children
Danika L. Hill et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu et al.
LANCET (2020)
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Jieliang Wang et al.
AAPS PHARMSCITECH (2020)
Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients
Carl A. Pierce et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Differences in the influenza-specific CD4 T cell immunodominance hierarchy and functional potential between children and young adults
Ian Shannon et al.
SCIENTIFIC REPORTS (2019)
The Unexplored Roles of Human Serum IgA
Ka Wai Leong et al.
DNA AND CELL BIOLOGY (2014)
FcαRI-Mediated Inhibition of IL-12 Production and Priming by IFN-γ of Human Monocytes and Dendritic Cells
Marylene Lecocq et al.
JOURNAL OF IMMUNOLOGY (2013)